Fundraising Fox

Terremotobio

South San Francisco, US · Founded 2022 · 6 known investors

terremotobio.com ↗

Terremoto Bio develops next-generation small-molecule therapies using medicinal chemistry, targeting previously "undruggable" disease areas. The company focuses on drug candidates designed for improved efficacy and patient outcomes.

BiotechDeep Tech

Founders & leadership

GL
Grace LuExecutive
JC
James ChristensenExecutive
CB
Charles BaumExecutive

Board

MG
Michael GollerBoard director
RHReid Huber
Reid Huberin𝕏DirectorPartner at Third Rock Ventures
PT
Peter ThompsonBoard director
DO
Daniel O'ConnellBoard director

Investors · 6

EcoR1 CapitalSan Francisco
OrbiMedNew York · $1M – $75M
RA CapitalBoston
Novo Holdingsreported · 2 sourcesCopenhagen · $1.1M – $54M
Osage University Partnersreported · 2 sourcesBala Cynwyd
Third Rock Venturesreported · 3 sourcesBoston · $100K – $5M

Reported raises · per SEC filings

Form D private placements

$40.7M disclosed across 1 round · 2026

▶$40.7MraisedApr 2026 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael GollerDirector
  • Grace LuExecutive Officer
  • James ChristensenExecutive Officer, Director
  • Reid HuberDirector
  • Peter ThompsonDirector
  • Daniel O'ConnellDirector
  • Charles BaumExecutive Officer, Director
Offering amount
$108.6M
Amount sold
$40.7M
First sale
Apr 2026
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Terremotobio went on to found or lead other companies.

Peter ThompsonChairman, Co-FounderFounded Cleave Biosciences +3Reid HuberDirectorFounded MOMA Therapeutics +2

In the news

Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series Bfiercebiotech.com · Aug 2026Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology and Hereditary Hemorrhagic Telangiectasiabusinesswire.com · Apr 2026Terremoto Biosciences Raises $108M to Advance Targeted AKT1 Programs | citybizcitybiz.co · Apr 2026Terremoto takes $108M series C to fuel clinical trials of AKT1 inhibitorsfiercebiotech.com · Apr 2026Terremoto Biosciences Raises $108M in Series C Fundingfinsmes.com · Apr 2026Terremoto Biosciences secures $175m in series B funding, total capital hits $250m By Investing.cominvesting.com · Nov 2023

Frequently asked questions

What does Terremotobio do?
Terremoto Bio develops next-generation small-molecule therapies using medicinal chemistry, targeting previously "undruggable" disease areas. The company focuses on drug candidates designed for improved efficacy and patient outcomes.
Who are Terremotobio's investors?
Terremotobio's investors include EcoR1 Capital, OrbiMed, RA Capital, Novo Holdings, Osage University Partners, Third Rock Ventures.
How much funding has Terremotobio raised?
Terremotobio has disclosed $40.7M raised across 1 round.
Where is Terremotobio headquartered?
Terremotobio is headquartered in South San Francisco, US.